About this trial
This early phase I trial determines where and to what degree the tracer \[68Ga\] Ga-FAPI-04 accumulates in normal and cancer tissues in patients with high grade neuroendocrine cancer. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research \[68Ga\] Ga-FAPI-04. Because some cancers take up \[68Ga\] Ga-FAPI-04, it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body.
Eligibility criteria
Qualifiers
Age ≥ 18 years old
Previous low uptake of [68Ga] Ga-DOTATATE PET/CT scan OR
Krenning Score ≥ 3 OR
Ki67 index ≥ 20%
Disqualifiers
Pregnancy or lactation
Patient recently underwent surgery with wound healing
Trial design
Treatments tested in this trial
- Computed Tomography
- Gallium Ga 68-DOTA-FAPI-04
- Positron Emission Tomography
Treatment groups
Sponsors and collaborators
University of Michigan Rogel Cancer Center
Lead sponsor
Neuroendocrine Research Foundation
Collaborator